Abstract
The approval of the oral direct thrombin inhibitor dabigatranetexilat and the oral factor Xa inhibitors rivaroxaban and apixaban as thromboprophylaxis challenges the position of the vitamin K antagonists (VKA). Predictable pharmacodynamics gives the new oral anticoagulants an advantageous profile. Unlike VKAs there is no specific reversal agent available for the new oral anticoagulants. Experience with haemostatic products for the emergency management of critical bleeding caused by these agents is limited.
MeSH terms
-
Administration, Oral
-
Anticoagulants / administration & dosage
-
Anticoagulants / adverse effects
-
Anticoagulants / pharmacology
-
Antithrombins / administration & dosage
-
Antithrombins / adverse effects
-
Antithrombins / pharmacology
-
Blood Coagulation Factors / therapeutic use
-
Blood Coagulation Tests
-
Dabigatran / administration & dosage
-
Dabigatran / adverse effects
-
Dabigatran / antagonists & inhibitors*
-
Dabigatran / pharmacology
-
Drug Monitoring / methods*
-
Factor Xa Inhibitors / administration & dosage
-
Factor Xa Inhibitors / adverse effects
-
Factor Xa Inhibitors / pharmacology
-
Hemorrhage / chemically induced
-
Hemorrhage / drug therapy
-
Humans
-
Plasma
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects
-
Pyrazoles / antagonists & inhibitors*
-
Pyrazoles / pharmacology
-
Pyridones / administration & dosage
-
Pyridones / adverse effects
-
Pyridones / antagonists & inhibitors*
-
Pyridones / pharmacology
-
Rivaroxaban / administration & dosage
-
Rivaroxaban / adverse effects
-
Rivaroxaban / antagonists & inhibitors*
-
Rivaroxaban / pharmacology
-
Vitamin K / administration & dosage
-
Vitamin K / adverse effects
-
Vitamin K / antagonists & inhibitors
-
Vitamin K / pharmacology
Substances
-
Anticoagulants
-
Antithrombins
-
Blood Coagulation Factors
-
Factor Xa Inhibitors
-
Pyrazoles
-
Pyridones
-
Vitamin K
-
apixaban
-
Rivaroxaban
-
Dabigatran